Revance Therapeutics, Inc. financial data

Symbol
RVNC on Nasdaq
Industry
Pharmaceutical Preparations
Location
1222 Demonbreun Street, Suite 2000, Nashville, TN
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 418 % -11.5%
Quick Ratio 75.2 % +83.7%
Debt-to-equity -458 % +81.8%
Return On Equity 136 % -92.3%
Return On Assets -38 % +48.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 105M shares +19.5%
Common Stock, Shares, Outstanding 105M shares +19.5%
Entity Public Float 2.2B USD +120%
Common Stock, Value, Issued 105K USD +19.3%
Weighted Average Number of Shares Outstanding, Basic 104M shares +20.3%
Weighted Average Number of Shares Outstanding, Diluted 104M shares +20.3%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 257M USD +25.8%
Research and Development Expense 77.2M USD +21.9%
Operating Income (Loss) -290M USD -1.66%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -36.6M USD +6.46%
Income Tax Expense (Benefit) 1.5M USD +400%
Net Income (Loss) Attributable to Parent -184M USD +55.5%
Earnings Per Share, Basic -1.97 USD/shares +61.2%
Earnings Per Share, Diluted -1.97 USD/shares +61.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 58.6M USD -67.3%
Cash, Cash Equivalents, and Short-term Investments 184M USD -38.7%
Accounts Receivable, after Allowance for Credit Loss, Current 48.3M USD +89.9%
Inventory, Net 85.2M USD +84.4%
Assets, Current 330M USD -15.1%
Property, Plant and Equipment, Net 15.9M USD -7.46%
Operating Lease, Right-of-Use Asset 48M USD -12.4%
Intangible Assets, Net (Excluding Goodwill) 7.63M USD -27.3%
Goodwill 0 USD -100%
Other Assets, Noncurrent 172K USD -26.8%
Assets 462M USD -13.3%
Accounts Payable, Current 12.3M USD +158%
Employee-related Liabilities, Current 10.4M USD -60.1%
Accrued Liabilities, Current 34M USD -36.4%
Contract with Customer, Liability, Current 6.33M USD +17.8%
Liabilities, Current 80M USD -2.57%
Contract with Customer, Liability, Noncurrent 85.6M USD +1.47%
Operating Lease, Liability, Noncurrent 35M USD -17.1%
Other Liabilities, Noncurrent 2.91M USD +2.68%
Liabilities 625M USD -2.21%
Accumulated Other Comprehensive Income (Loss), Net of Tax 72K USD
Retained Earnings (Accumulated Deficit) -2.21B USD -9.12%
Stockholders' Equity Attributable to Parent -163M USD -53.5%
Liabilities and Equity 462M USD -13.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -65.9M USD +5.12%
Net Cash Provided by (Used in) Financing Activities 92.8M USD +2743%
Net Cash Provided by (Used in) Investing Activities -31.7M USD -133%
Common Stock, Shares Authorized 190M shares 0%
Common Stock, Shares, Issued 105M shares +19.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -4.82M USD -117%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 64.6M USD -65.4%
Deferred Tax Assets, Valuation Allowance 496M USD +15.9%
Deferred Tax Assets, Gross 514M USD +17.1%
Operating Lease, Liability 41.4M USD -18.7%
Payments to Acquire Property, Plant, and Equipment 1.71M USD +96.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -184M USD +55.4%
Lessee, Operating Lease, Liability, to be Paid 56.9M USD -19.5%
Property, Plant and Equipment, Gross 37.2M USD -22.5%
Operating Lease, Liability, Current 6.37M USD -26.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 11.2M USD +3.05%
Lessee, Operating Lease, Liability, to be Paid, Year One 10.9M USD +3.46%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 15.5M USD -21.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 4.54M USD -59.4%
Deferred Tax Assets, Operating Loss Carryforwards 377M USD +13%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 12.9M USD +32.8%
Lessee, Operating Lease, Liability, to be Paid, Year Four 4.02M USD -11.4%
Operating Lease, Payments 2.56M USD +22.6%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 6.13M USD -56.8%
Depreciation, Depletion and Amortization 1.98M USD -53.9%
Deferred Tax Assets, Net of Valuation Allowance 18.6M USD +59.3%
Share-based Payment Arrangement, Expense 35.2M USD -20.1%
Interest Expense 20.1M USD +5.65%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%